Tacrolimus 0.03% w/w is a topical calcineurin inhibitor (TCI) immunosuppressant ointment. It is a macrolide lactone derived from the bacterium *Streptomyces tsukubaensis*. In the Indian context, it is a critical non-steroidal topical agent for managing moderate to severe atopic dermatitis, providing an alternative to topical corticosteroids, especially for sensitive areas like the face, eyelids, and neck. It works by selectively inhibiting T-lymphocyte activation, thereby suppressing the inflammatory cascade responsible for eczema.
Adult: Apply a thin layer of 0.03% ointment to the affected area(s) twice daily. Rub in gently and completely. Use the lowest effective dose and frequency. For long-term management, transition to a twice-weekly application to previously affected areas to prevent flares.
Note: 1. Apply only to affected skin. 2. Wash hands before and after application (unless hands are treated). 3. Do not cover with occlusive dressings or bandages. 4. Do not apply to wet skin; ensure skin is completely dry. 5. Avoid exposure to sunlight, sunlamps, and tanning beds. Use protective clothing and sunscreen. 6. Do not use for prophylaxis. 7. Do not swallow the ointment.
Tacrolimus binds with high affinity to the intracellular immunophilin FKBP-12 (FK506 binding protein-12). This tacrolimus-FKBP-12 complex specifically and potently inhibits the calcium-dependent serine-threonine phosphatase, calcineurin. Inhibition of calcineurin prevents the dephosphorylation and subsequent nuclear translocation of the cytosolic component of the nuclear factor of activated T-cells (NF-AT). This blocks the transcription and synthesis of early T-cell activation cytokines, most notably interleukin-2 (IL-2), as well as IL-3, IL-4, IL-5, GM-CSF, TNF-α, and IFN-γ.
Pregnancy: Pregnancy Category C. Animal studies have shown fetotoxicity and embryotoxicity at high systemic doses. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Avoid extensive or long-term use.
Driving: No known effects. However, if application causes burning or itching, it may temporarily distract the patient.
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Fluconazole, Clarithromycin, Erythromycin, Diltiazem, Verapamil, Cimetidine) | May increase systemic blood levels of tacrolimus if absorbed, potentially increasing the risk of systemic adverse effects. | Moderate |
| CYP3A4 Inducers (e.g., Rifampicin, Phenytoin, Phenobarbital, Carbamazepine, St. John's Wort) | May decrease the efficacy of tacrolimus by increasing its metabolism. | Moderate |
| Other Immunosuppressants (e.g., systemic corticosteroids, cyclosporine) | Concomitant use may potentiate systemic immunosuppression, increasing risk of infections and malignancies. | Major |
| Live Vaccines (e.g., MMR, Varicella, Yellow Fever) | Theoretical risk of diminished immune response and potential for vaccine-induced infection. Avoid vaccination during treatment. | Major |
Same composition (Tacrolimus (0.03% w/w)), different brands: